1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

Authors:
  • DMD. Miles
    D. Miles
  • DCD. Cameron
    D. Cameron
  • IBI. Bondarenko
    I. Bondarenko
  • MLM. Lyudmila
    M. Lyudmila
  • JAJ.C. Alcedo
    J.C. Alcedo
  • RLR.I. Lopez
    R.I. Lopez
  • SIS.A. Im
    S.A. Im
  • JCJ.L. Canon
    J.L. Canon
  • YSY. Shparyk
    Y. Shparyk
  • DYD. Yardley
    D. Yardley
  • NMN. Masuda
    N. Masuda
  • JRJ. Ro
    J. Ro

Abstract
No abstract available